Fentanyl Injectable Solution Recalled for Sterility Validation Failure
Central Admixture recalls 8,146 bags of fentanyl injection due to lack of sterilization cycle validation. This Class II recall affects patients nationwide who may receive contaminated IV medication.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a high-risk injectable opioid due to lack of sterilization validation. Although no illnesses or injuries have been reported, the potential for microbial contamination of a potent opioid product poses significant risk to patients receiving intravenous administration.
Plain-English summary
Central Admixture Pharmacy Services Inc. is recalling fentanyl in 0.9% sodium chloride (2500 mcg/250 mL) injectable solution. The recall affects 8,146 bags distributed nationwide, with multiple lot numbers and expiration dates ranging from July through September 2023.
The recall is due to lack of assurance of sterility resulting from lack of validation data for sanitization cycles. The manufacturer failed to adequately validate that its sterilization processes ensure the product remains sterile and safe for intravenous administration.
This prescription fentanyl injection was distributed nationwide in the United States. Fentanyl is a potent opioid used for pain management and anesthesia, typically administered intravenously in healthcare settings. The concern is that patients may have received contaminated medication if affected lots were used.
The recalled product
- Product
- fentaNYL in 0.9% sodium chloride, 2500 mcg/250 mL, (10 mcg/mL), 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-5
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable Opioid
- Affected units
- 8,146
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 17-270584
- 17-270586
- 17-270597
- 17-270613
- Exp. 7/17/2023
- 17-270655
- 17-270659
- 17-270741
- Exp. 7/18/2023
- 17-270872
- 17-270875
- Exp. 7/20/2023
- 17-271040
- 17-271041
- 17-271042
- 17-271058
- 17-271066
- 17-271071
- 17-271080
- Exp. 7/24/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Central Admixture Pharmacy Services Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services Inc
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighFentanyl injectable syringes recalled nationwide for sterility assurance failure
FDA (Drugs) · 2023-10-11
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereBone Marrow Tray kits recalled due to sterility failure
FDA (Devices) · 2026-07-22